Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma ModelBeatrice Anna Zannetti, Francesco Lanza, Giovanni Poletti et al.|Cells|2020Cited by 20
Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 PatientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2010Cited by 7
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDMAnnamaria Brioli, Michèle Cavo, Letizia Canepa et al.|Blood|2014Cited by 3
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)Paola Tacchetti, Michèle Cavo, Carolina Terragna et al.|Blood|2011Cited by 1
Prognostic impact of cytogenetic abnormalities in newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: A prospective analysis of 593 patientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|F1000Research|2010Cited by 0